Non-T-cell antigens

Non-T-cell antigens refer to a broad category of molecules, including lineage-specific proteins and carbohydrates, that are primarily expressed on cells other than T-lymphocytes, such as B-cells, myeloid cells, or tumor cells of non-lymphoid origin [NIH, ClinicalTrials.gov]. In clinical oncology, the aberrant expression of these antigens on malignant T-cells—often termed lineage infidelity—serves as a vital diagnostic indicator for T-cell lymphomas and provides a therapeutic window for using targeted agents like Rituximab (anti-CD20) or Gemtuzumab ozogamicin (anti-CD33) in T-cell diseases [NIH, TandfOnline]. Furthermore, the category includes Tumor-Associated Carbohydrate Antigens (TACAs), such as GD2 and Globo H, which are considered non-T-cell antigens because they do not form peptide-MHC complexes and thus require specialized targeting by monoclonal antibodies like Dinutuximab or carbohydrate-based vaccines [Life Science Exchange]. The term is also central to the production of Anti-thymocyte Globulin (ATG), where antibodies against non-T-cell antigens (e.g., on red blood cells or monocytes) are removed during manufacturing to ensure the drug's immunosuppressive activity is specific to T-cells [Health Canada, ClinicalTrials.gov]. Additionally, non-T-cell antigens include T-independent antigens that can stimulate B-cell antibody production without T-cell assistance [NIH]. Consequently, these antigens are critical for both the development of lineage-specific immunotherapies and the refinement of diagnostic flow cytometry.

Other names

Non-lineage antigensAberrant antigensLineage-infidelity antigensT-independent antigensTumor-associated carbohydrate antigens (TACAs)Non–T-cell antigens

Targeted cell depletion via antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), or B-cell stimulation through T-independent pathways.